Testosterone Articles
Approvable letter for Alza's Ionsys
2 August 2004
Stock Commentary - New York
26 July 2004
ASCEND starts Ph II Andrin trial in Australia
26 July 2004
Endo Pharma sees 2nd-qtr profits slump
26 July 2004
EU green light for Schering AG's Nebido
19 July 2004
Stock Commentary - Europe
19 July 2004
Fall re-launch for GSK's NiQuitin CQ
19 July 2004
Cellegy and Strakan in Tostrex deal
19 July 2004
ASCEND Thera licenses Andrin for North America
12 July 2004
Tokyo pharma stocks - week to July 5
12 July 2004
Dermatrends gains patent on amine drug delivery tech
12 July 2004
Columbia starts MRP in EU for Striant SR
5 July 2004
Watson's Oxytrol OKed in Canada
5 July 2004
NexMed raises $8.27M from private placement
28 June 2004
Watson's oxybutynin patch gets EU OK
28 June 2004
New research reveals role of hormones in men
28 June 2004
P&G's Intrinsa offers hope to women
21 June 2004
Noven and Shire in ADHD patch deal
21 June 2004
Schering AG's Menostar approved in the USA
14 June 2004
Ardana's Striant SR available in the UK
7 June 2004
Bentley's revenues rise 15.4% for 1st-qtr 2004
10 May 2004
Ardana gets OK for Striant SR in the UK
10 May 2004
Auxilium and Ipsen sign Testim agreement
12 April 2004
Cellegy's revenues climb 16% in 2003
5 April 2004
Chinese approval for LAM Pharma's wound gel
29 March 2004
Recordati pharma sales up, net slumps
22 March 2004
Study shows long-term benefits of Testim
8 March 2004
Bentley's sales hit record $64.7 million
8 March 2004
NexMed licenses Femprox out in South Korea
23 February 2004
Tokyo pharma stocks - week to Feb 16
23 February 2004
Vivus licenses two products from Acrux
23 February 2004
FDA clears Solvay's EstroGel
16 February 2004
Schering AG's Climara Pro launched in USA
16 February 2004
Auxilium and Bayer sign Testim deal
9 February 2004
J&J 4th-qtr EPS up 35%, sales rise 20%
26 January 2004
Paladin signs licensing accord with Watson
19 January 2004
Noven earns $500,000 milestone from P&G Pharma
5 January 2004
First EU approval for Schering AG's Nebido
15 December 2003
Stock Commentary - New York
17 November 2003
Positive Ph II data for BioSante's LibiGel
3 November 2003
J&J raises forecast on strong 3rd quarter
20 October 2003
Watson licenses novel product to UCB
6 October 2003
Acquisition charges hit J&J 2nd-qtr results
21 July 2003
FDA rejects Cellegy's testosterone gel
14 July 2003
FDA extends review time for Novavax' Estrasorb
7 July 2003
Auxilium's Testim cleared in UK
7 July 2003
Positive Testim data from landmark study
23 June 2003
Barr completes deal to acquire Wyeth prods
16 June 2003
Oxytrol accepted for review in Canada
2 June 2003
Adderall drives growth at Shire in 1st quarter
12 May 2003
Stock Commentary - Europe
5 May 2003
Noven gains $25M from Shire
14 April 2003
ProEthic transdermal ketoprofen deal
14 April 2003
LAM Pharma signs sales rep deal with SRI
31 March 2003
Watson signs sales force deal with Ventiv
24 March 2003
Noven to repurchase stock
10 March 2003
Stock Commentary - Europe
10 March 2003
Shire's profits up on switching strategy
3 March 2003
Watson's incontinence patch cleared by US FDA
3 March 2003
Novavax completes $16.6M financing
24 February 2003
Noven doubles incomes in 2nd qtr; Novogyne up 127%
19 August 2002
US study finds Rx and tobacco "collaboration"
19 August 2002
Columbia files for buccal testosterone product
19 August 2002
J&J
22 July 2002
Schering AG gets Euro Testogel rights
8 July 2002
Novavax gets $10M from King Pharma
8 July 2002
Tokyo pharma stocks - week to June 24
1 July 2002
NexMed raises $5M from note and warrants issue
24 June 2002
Durogesic cleared in UK for chronic pain
3 June 2002
Noven's Phase II MethyPatch study successful
8 April 2002
Strakan launches home-grown acne drug Zindaclin in UK
25 March 2002
Auxilium files NDA for gel-based testosterone drug
11 March 2002
Noven Pharma boost from JV revenues
4 March 2002
Cellegy losses deepen as sales to Gryphon fall
25 February 2002
Watson sees 2001 revenues, income rise
25 February 2002
Pretax profits down at Belgium's Solvay
18 February 2002
Pharmacia & Paladin sign Canadian distribution deal
28 January 2002
Aderis Pharma plans $100 million IPO.
21 January 2002
BioSante licenses rights to Combi Gel from Antares Pharma
14 January 2002
Amarin sells Argentine transdermal patch unit
12 December 2001
MediGene files first application for Leuprogel
5 December 2001
Cellegy acquires Vaxis Therapeutics
30 November 2001
Axis-Shield signs deal with Abbott
23 November 2001
Contraceptive patch from J&J is first cleared in USA
21 November 2001
FDA filing ahead of schedule for Tostrex
8 November 2001
Atrix submits NDA to FDA for Leuprogel three-month product
28 September 2001
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
